our quarter for December ended you, want Thank everyone year-end the XX, Susan. I fourth and welcome call to XXXX. to
a of provide overview quick very I'll First, XXXX.
end QX march forward. extraordinarily challenging, runway XXXX. been continued We to biotech steady cash market a the has While extended our of the Aptose
in and a or talented acute development luxeptinib. team. the myeloid of We formulation began strides leukemia, of we importantly, continued building for and made for tuspetinib treatment experienced significant We the testing a And most AML. new created
important having and differentiated safe also emphasize to demonstrated very or with want relaptorefractory are comes of while or in These tuspetinib are having to cell we treated call I best responses both Having investigational aggressive well failed attributes remissions the other it, patients drugs without toxicities an a reverse It's cases, beyond. and Tus. I/II hematopoietic in escalation highly that been also potency and to progression. as today, and to extraordinary fourth it various many it's line, the unpack will agent and dose the antileukemic being achieve an prior When to transplants. has typical stem third causing complete to line disease available in TUS, such profile, of safety deliver population to ill the the formal failed approved It's we cancer patients These the therapies, date tuspetinib, for or highlight incredibly AML exploration Phase potency dose agents. tolerated. difficult to treat AML trial. And typically in
alterations these What diversity disease. more extreme highly to the is by adverse treat makes even their genetic epigenetic and difficult patients expressed of
more of dose X far and of treatment other ADMIRAL inhibitors with from are The contrast, tested patients FLTX which and FLTX billing transplants AML. agents half inhibitor. failed X/X prior not entering prior hypomethylating responses half failed commercial having therapy for our with inhibitor, experienced In than venetoclax, ago, second in billing a mutant the trial recall were you the patients HMAs, this XX% more had essentially a gilteritinib, during venetoclax. treatment FLTX If having the trial seen not line, FLTX seen had years was prior with patients or
of an levels, those XXX were no dose XX with activity. it of unprecedented patients. across does milligram, shown active dose Tus FLTX patients, Tus well responses observed with in delivers levels. mutated X From breadth responses milligram, DLTs a delivered XX-milligram FLTX wild-type as once-daily perspective, of Nevertheless, and dosing convenient, tablets in has mutation Tus any oral and as XXX milligram, has sensitivity
We TPXX as and with FLTX the patients splicing in patients as difficult-to-treat the having alterations mutations, seen patients NPMX factors, and and also MLL very well RUNXX, having responses have in ASXXX genes. DNMTXA, IDHX co-mutations, AML
most But mechanism drugs. one Mutations of to pathway relapsed/refractory many other is resistance AML in the the an RAS interesting the observations with generate escape RAS in to mutations. activity patients serving
RAS However, overall response mutations, measured in rate. CR/CRH have including we XX% XX% rate response a with a patients
one and mutation pathway. in fact, RAS a mutation PTPNXX, the a patient In a mutation in had representing RAS dual
year in response RAS need rate We of this if will high population a monitor to patients approval RAS-mutated for trials. may patients accelerated determine future represent AML mutated and continue the AML relapsed/refractory unmet
package, As doses for will agent trials. and our of single minutes, high We've Tus of and wrapped in study and the we of detail escalation combination in a in patients safety in I/II and formal demonstrated successful in And patients up responses. trial. venetoclax. strong data in and we to a highly effective bone our Dr. safe Behar Tus reduce expansion assembled We We've exploration further treated with trial. a achieve ACTIVATE dramatically agent a XX date blast to selected describe Phase drug dose ability to few over that dose fraction dose marrow a combination initiated single we
monotherapy array approval patients a we year, receive guide an trial accelerated In ACTIVATE will dosing, Tus/VEN Tus VEN a or path second-line is as support combination registrational This to combination to as a certain doublet patients. doublet. ACTIVATE in with parallel can referred plus with to AML of broad to AML trials request with pilot of frontline hypomethylating being the we conversations FDA high will venetoclax study unmet in treat doublet Tus the to populations the Tus Tus/VEN TUS/VEN/HMA and a AML in to this of bridge that we plus serve conducted so plus the to data agent patients patients triplet need. a enrich the our of patient for In monotherapy collect a
clearly will with combination a as can agent, TUS other Tus drug and drugs. goal single commercial in deliver of ultimate success be the responses for or any While AML
week, patients on plan this additional XXXX. initiate we enrollment throughout we doublet As will in TUS/VEN the we of Once this with doublet, and gain we patients the Tus/VEN HMA have of doublet, on the place to patients. begun experience AML frontline triplet
precisely blending of be AML also drugs revolve patients, around Such deep populations The the therapy will of future ideal partner that and and of broad side deep positioned into can lines and addition AML require is safety earlier of drugs become will convenience describes because cocktails unnecessarily cardiotoxicities therapy without complicating its to once-daily other remissions activity its its to Tus take prolong a tolerated deliver myeloseparation oral Tus. best broad remissions. VEN/HMA for in as agent, can can profile. patients to doublet And the serve cocktails effects. this the of of
as triplet to toward Dr. activities maintenance for application patients, monotherapy approval relapsed/refractory with data you in combination Tus as date accelerated point of additional in Together, in second-line provide well doublet use accelerated as AML, a these Behar And therapy. color AML, as for in momentarily. frontline will in for approval therapy use
as Lux, to AML kinases BTK operative us kinase lymphomas and as Now FLTX to a and Lux, secondary AML. is as to clinical Lux small you in and active Lux's certain Many target patients We formulation, and it luxeptinib. stage a led in first-generation develop let turn lymphoma lymphomas patients of a already patient with inhibitor. ability clinically pipeline our CR briefly and that in CG-XXX. in is our as in agent. it to delivered DLBCL we B-cell program. it initial leukemias an a molecule reported leukemias a me typically refer Lux CR with demonstrating know GX oral administered patient or
single are in original also GX Lux. of B-cell patients and dose formulation up grade third it than developed formulation generation determine it to the formulation. achieved the GX we call formulation aware that You administrations because XXXX during absorption that malignancy formulation we represents XX-fold And AML the will new GX a and
of XXX lower at initiated dose original was dose GX highest the milligrams. of eighteenfold at an level the Because set we continuous XX of milligrams, dosing formulation
to target administer a formulation. to we does XX preliminary we dosing with and achieve at greater safety GX higher original the continue equivalent exposures plasma the plasma and patients, and continuous the AML hoped to GX roughly XX That suggest was of of GX And determine dose GX plan PK next, deliver We the if exposure milligrams data of to achieve collect indeed XXX milligrams milligrams GX. even of with levels. results can it
will keep EHA. around will our you We findings report likely preliminary and data posted on
in with which Dr. want Sanwal that also the Stephen I mention Manshu described Dr. Plus interferes One, modulates Lyn-mediated BCR and lymphoma in collaborators journal, the signaling article in of and of LYN, and the kinases Howell, at processes. to activity. entitled as to SiC autoimmunity pathway UCSD, Aptose and just the online inflammatory B-cell LCK activation or Lux published an on BTK relates of to we cancers receptor of and to influence LYN the Lux act This and downstream ability act role B-cell on as to well the at level Luxeptinib
So chance. if article please take a a look you the get at
during define with several plans to about biotech opportunity. the our asked We companies clinical drug to pharma that interest with potential our pleased In tuspetinib. big further our and to were we're help for tuspetinib. the often productive see It's commercial has clear such we priorities JPMorgan we in Finally, to engaged on January, partnerships these that growing. get discussions in need and radar what solidify extensive with is that an program companies and week, we of accomplish
safety is I combination some tuspetinib the limited the potentially triplet AML therapies and for as current proven previously. The mentioned superior of shifting activity combination by toward itself of for doublet Tus of and doublet despite are to use choice, us markets we've as and therapy. breadth paradigm to pharma its The treatment clinical and drug plans of The making big addressing and therapy, lends date somewhat And successes, combinations lines profile helped multiple a triplet have data and maintenance as clearly generated therapy, the prospective in tuspetinib most delineate and in therapy. including commercial sizable drug. AML toxicities
venetoclax, He questions be Medical will include extended of clinical Behar, single clinical in Chief combination plans, our therapy. afterwards. tuspetinib Dr. as a which with for speak Rafael Our our and available recently well as combination AML agent trial will ACTIVATE also about triplet Officer, in initiated as
resident Rafael clinical I our Raf? now over Dr. to our about will Bejar, it KOL, Medical more our to Chief talk turn plans. tuspetinib Officer,
